Malaria pharmacogenomics: return to the future
2013; Future Medicine; Volume: 14; Issue: 7 Linguagem: Inglês
10.2217/pgs.13.41
ISSN1744-8042
Autores Tópico(s)HIV/AIDS drug development and treatment
ResumoPharmacogenomicsVol. 14, No. 7 EditorialMalaria pharmacogenomics: return to the futureJP GilJP GilDrug Resistance Unit, Section of Pharmacogenetics, Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden and Institute of Biotechnology & Bioengineering, Center of Molecular & Structural Biomedicine, University of Algarve, Faro, Portugal and Department of Biological Sciences, The Harpur College of Arts & Sciences, Binghamton University, Binghamton, NY, USA. Published Online:8 May 2013https://doi.org/10.2217/pgs.13.41AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: malariananotechnologypharmacogeneticsresistanceReferences1 Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin. Drug Metab. Toxicol.7,1185–1200 (2011).Crossref, Medline, CAS, Google Scholar2 Achan J, Kakuru A, Ikilezi G et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N. Engl. J. Med.367,2110–2118 (2012).Crossref, Medline, CAS, Google Scholar3 Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther.271,557–566 (1994).Medline, CAS, Google Scholar4 Cavaco I, Martensson A, Froberg G, Msellem M, Bjorkman A, Gil JP. CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment. J. Infect. Dis.207,687–688 (2013).Crossref, Medline, Google Scholar5 Neiva A. Formação de raça do hepatozoátio do impaludismo rezistente à quinina. Mem. Inst. Oswaldo Cruz2,131–140 (1910).Crossref, Google Scholar6 Ursing J, Schmidt BA, Lebbad M et al. Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage? Infect. Genet. Evol.7,555–561 (2007).Crossref, Medline, CAS, Google Scholar7 Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ. Mefloquine pharmacokinetic–pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother.44,3414–3424 (2000).Crossref, Medline, CAS, Google Scholar8 Bethell D, Se Y, Lon C et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin. Infect. Dis.51,e105–e114 (2010).Crossref, Medline, CAS, Google Scholar9 Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in east Africa. Infect. Genet. Evol.7,562–569 (2007).Crossref, Medline, CAS, Google Scholar10 Malmberg M, Ferreira PE, Tarning J et al.Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J. Infect. Dis.207(5),842–847 (2013).Crossref, Medline, CAS, Google Scholar11 Barnes K. Antimalarial drugs and the control and elimination of malaria. In: Treatment and Prevention of Malaria (1st Edition). Staines H, Krishna S (Eds). Springer, Basel, Switzerland (2012).Google Scholar12 Staines HM, Derbyshire ET, Slavic K, Tattersall A, Vial H, Krishna S. Exploiting the therapeutic potential of Plasmodium falciparum solute transporters. Trends Parasitol.26,284–296 (2010).Crossref, Medline, CAS, Google Scholar13 Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet371,64–74 (2008).Crossref, Medline, CAS, Google Scholar14 Cui L, Wang Z, Miao J et al. Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum. Mol. Microbiol.86,111–128 (2012).Crossref, Medline, CAS, Google Scholar15 Ferreira EP, Cavaco I, Gil JP. Pharmacogenetic tools for malaria and TB in the developing world. Per. Med.5,627–639 (2008).Link, CAS, Google Scholar16 Principles and Practices of Malariology, Volume I. McGreggor I, Wernsdorfer W (Eds).Churchill-Livingstone, Edinburgh, UK (1988).Google Scholar101 NANOMAL project. www.nanomal.org/Google ScholarFiguresReferencesRelatedDetailsCited ByCYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy12 July 2021 | Frontiers in Genetics, Vol. 12Pharmacogenomics and pharmacoepigenomics: Impact on therapeutic strategiesCYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study1 February 2018 | Malaria Journal, Vol. 17, No. 1Complex Polymorphisms in the Plasmodium falciparum Multidrug Resistance Protein 2 Gene and Its Contribution to Antimalarial Response29 September 2014 | Antimicrobial Agents and Chemotherapy, Vol. 58, No. 12 Vol. 14, No. 7 Follow us on social media for the latest updates Metrics Downloaded 137 times History Published online 8 May 2013 Published in print May 2013 Information© Future Medicine LtdKeywordsmalariananotechnologypharmacogeneticsresistanceFinancial & competing interests disclosureThis work was supported in part by FP7/EDCTP network Grant IP.2007.31060.002, 'An integrated approach to clinical trials, capacity building and networking in West Africa' and by EU FP7 grant ref. 304948 'Development of a Handheld Anti-malarial Diagnostic Device using Nanowire Technology'. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)